Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096889 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2METNFE2L2SNCAHPGD | |
| SCHEMBL6949870 | 0.94 | MET (0.50) | SMN1; SMN2METNFE2L2SNCAHPGD | |
| SCHEMBL6949866 | 0.94 | MET (0.50) | SMN1; SMN2METNFE2L2SNCAHPGD | |
| SCHEMBL6949573 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2METCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6949570 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2METCYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL6951842 | 0.89 | MET (0.48) | SMN1; SMN2METNFE2L2SNCAHPGD | |
| Hydrochloric Acid SCHEMBL6951884 | 0.89 | MET (0.48) | SMN1; SMN2METNFE2L2SNCAHPGD | |
| Hydrochloric Acid SCHEMBL6951847 | 0.89 | MET (0.48) | SMN1; SMN2METNFE2L2SNCAHPGD | |
| Hydrochloric Acid SCHEMBL6952311 | 0.89 | MET (0.48) | SMN1; SMN2METNFE2L2SNCAHPGD | |
| Hydrochloric Acid SCHEMBL6951891 | 0.89 | MET (0.48) | SMN1; SMN2METNFE2L2SNCAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148244-B2 | Medicines in controlling Vpr function | NIPPON SHINYAKU CO. LTD. (JP) | 2006-12-12 | — | — | US | claimed |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | D.WESTERN THERAPEUTICS INSTITUTE (JP) | 2006-06-15 | — | — | US | claimed |
| CN-1237969-C | therapeutic agent for chronic articular rheumatism | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | claimed |
| EP-1547596-A1 | MEDICINAL COMPOSITION AND METHOD FOR TREATING MALIGNANT TUMOR AND UTILIZATION THEREOF | D. Western Therapeutics Institute (JP) | 2005-06-29 | — | — | EP | claimed |
| US-20040209927-A1 | Medicines | NIPPON SHINYAKU CO. LTD. (JP) | 2004-10-21 | — | — | US | claimed |
| US-20040116481-A1 | Remedial agent for chronic articular rheumatism | NIPPON SHINYAKU CO. LTD. (JP) | 2004-06-17 | — | — | US | claimed |
| CN-1501801-A | therapeutic agent for chronic articular rheumatism | 日本新药株式会社 | 2004-06-02 | — | — | CN | claimed |
| EP-1382335-A1 | MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-01-21 | — | — | EP | claimed |
| EP-1378237-A1 | REMEDIAL AGENT FOR CHRONIC ARTICULAR RHEUMATISM | Nippon Shinyaku Co., Ltd. (JP) | 2004-01-07 | — | — | EP | claimed |
| EP-0754682-B9 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2003-09-17 | — | — | EP | claimed |
| EP-0754682-B1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2001-10-17 | — | — | EP | claimed |
| US-5972976-A | FOR TREATMENT OF VARIOUS MALIGNANT TUMORS; (E)-4-(2-(2-(N-acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine-1-oxide for example | NIPPON SHINYAKU COMPANY, LIMITED | 1999-10-26 | — | — | US | claimed |
| EP-0754682-A1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-01-22 | — | — | EP | claimed |
| US-7148244-B2 | Medicines in controlling Vpr function | NIPPON SHINYAKU CO. LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | D.WESTERN THERAPEUTICS INSTITUTE (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1237969-C | therapeutic agent for chronic articular rheumatism | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| EP-0754682-B9 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2003-09-17 | — | — | EP | disclosed |
| EP-0754682-B1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-5972976-A | FOR TREATMENT OF VARIOUS MALIGNANT TUMORS; (E)-4-(2-(2-(N-acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine-1-oxide for example | NIPPON SHINYAKU COMPANY, LIMITED | 1999-10-26 | — | — | US | disclosed |
| EP-0754682-A1 | AMINOSTILBAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209927-A1 | Medicines | SARS1, ADRA1B, ADRB1 | SMN1; SMN2 4197/4885MET 2520/4885NFE2L2 3065/4885 |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | IL4I1, AADAT, BCAT2 | SMN1; SMN2 4297/4885MET 200/4885NFE2L2 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.